Dr. Sven Borchmann studied economics in St. Gallen, Switzerland and Perth, Australia from 2006-2011 and medicine in Cologne, Germany from 2009–2015. He completed his doctorate in 2016 in the group of Prof. Elke Pogge von Strandmann. In his doctoral thesis he focused on the development of new bispecific antibody therapies for colon cancer.

In 2015 Dr. Borchmann joined the Department of Internal Medicine I at the Cologne University Hospital under the direction of Prof. Michael Hallek. During his clinical training, he worked as a study physician in the German Hodgkin Study Group under the direction of Prof. Andreas Engert and published several papers on clinical issues in Hodgkin lymphoma, including a translational paper on vitamin D deficiency in Hodgkin lymphoma and its effect on chemotherapy efficacy. For this research, he has been awarded the Else Kröner Fresenius Publication Prize. In 2016, Dr. Borchmann undertook part of his training at the Memorial Sloan Kettering Cancer Center in New York under the direction of Prof. Anas Younes. From 2017 to 2019, Dr. Borchmann was a Fellow of the Else Kröner Fresenius Research College Clonal Evolution in Cancer and joined the laboratory of Prof. Ullrich in Cologne, Germany as a postdoctoral researcher. During this time, he focused on the development of combination immunotherapies in various cancer mouse models, which have been difficult to treat with conventional immunotherapeutic approaches. Since 2020, Dr. Borchmann is an independent group leader and heads the working group for translational tumour genetics and immunotherapy. He is a member of the ESMO Gender Medicine Task Force.